Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,342 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,342 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $5.06, for a total value of $16,910.52. Following the completion of the sale, the chief executive officer owned 336,764 shares in the company, valued at approximately $1,704,025.84. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.69, for a total value of $312,950.00.

Lexeo Therapeutics Trading Up 14.3%

LXEO traded up $0.64 during trading hours on Wednesday, hitting $5.12. The company’s stock had a trading volume of 1,834,961 shares, compared to its average volume of 970,618. Lexeo Therapeutics, Inc. has a fifty-two week low of $2.51 and a fifty-two week high of $10.99. The firm has a market capitalization of $402.03 million, a PE ratio of -3.53 and a beta of 1.52. The company has a 50-day simple moving average of $6.00 and a 200 day simple moving average of $7.59.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Research analysts expect that Lexeo Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Chardan Capital reiterated a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.88.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds have recently modified their holdings of LXEO. RA Capital Management L.P. acquired a new position in shares of Lexeo Therapeutics during the 4th quarter valued at $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $47,299,000. Balyasny Asset Management L.P. bought a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth $16,117,000. Avoro Capital Advisors LLC bought a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $32,769,000. Finally, State Street Corp boosted its stake in shares of Lexeo Therapeutics by 485.1% during the 4th quarter. State Street Corp now owns 3,187,722 shares of the company’s stock worth $31,654,000 after acquiring an additional 2,642,877 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.